Vortioxetine: A review of efficacy, safety and tolerability with a focus on cognitive symptoms in major depressive disorder

Expert Opinion on Drug Safety

Volumn 14, Issue 8, 2015, Pages 1291-1304

  Al Sukhni, Mayce ^a   Maruschak, Nadia A ^b   McIntyre, Roger S ^b,c  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Antidepressant; Cognition; Major depressive disorder; Neurotransmitter; Vortioxetine

Indexed keywords

ESCITALOPRAM; GLUTAMIC ACID; SEROTONIN RECEPTOR; SEROTONIN TRANSPORTER; VENLAFAXINE; VORTIOXETINE; ANTIDEPRESSANT AGENT; PIPERAZINE DERIVATIVE; SEROTONIN UPTAKE INHIBITOR; SULFIDE;

ANTIDEPRESSANT ACTIVITY; ARTICLE; CARDIOVASCULAR RISK; COGNITION; COGNITIVE DEFECT; CONSTIPATION; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; GASTROENTERITIS; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERHIDROSIS; INFLUENZA; INSOMNIA; MAJOR DEPRESSION; MONTGOMERY ASBERG DEPRESSION RATING SCALE; NAUSEA; NEUROTRANSMISSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHINOPHARYNGITIS; SEXUAL DYSFUNCTION; SINUSITIS; SOMNOLENCE; THERAPY EFFECT; UPPER RESPIRATORY TRACT INFECTION; VOMITING; XEROSTOMIA; ADULT; DEPRESSIVE DISORDER, MAJOR; DRUG EFFECTS; PATHOPHYSIOLOGY;

ADULT; ANTIDEPRESSIVE AGENTS; COGNITION; DEPRESSIVE DISORDER, MAJOR; HUMANS; PIPERAZINES; SEROTONIN UPTAKE INHIBITORS; SULFIDES;

EID: 84937250292     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2015.1046836     Document Type: Article

References (51)

1. Rosenzweig-Lipson S, Beyer CE, Hughes ZA, et al. Differentiating antidepressants of the future: Efficacy and safety. Pharmacol Ther 2007;113:134-53
2. Pehrson AL, Sanchez C. Serotonergic modulation of glutamate neurotransmission as a strategy for treating depression and cognitive dysfunction. CNS Spectr 2014;19:121-33
3. Trintellix (vortioxetine) [product monograph]. Lundbeck Canada Inc; Montreal, QC: 2014
4. Areberg J, Sogaard B, Hojer AM. The clinical pharmacokinetics of Lu AA21004 and its major metabolite in healthy young volunteers. Basic Clin Pharmacol Toxicol 2012;111:198-205
5. Chen G, Lee R, Hojer AM, et al. Pharmacokinetic Drug Interactions Involving Vortioxetine (Lu AA21004), a Multimodal Antidepressant. Clin Drug Investig 2013;33:727-36
6. Hvenegaard MG, Bang-Andersen B, Pedersen H, et al. Identification of the cytochrome P450 and other enzymes involved in the in vitro oxidative metabolism of a novel antidepressant, Lu AA21004. Drug Metab Dispos 2012;40:1357-65
7. Bang-Andersen B, Ruhland T, Jorgensen M, et al. Discovery of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl] piperazine (Lu AA21004): A novel multimodal compound for the treatment of major depressive disorder. J Med Chem 2011;54:3206-21
8. Pehrson AL, Cremers T, B-etry C, et al. Lu AA21004, a novel multimodal antidepressant, produces regionally selective increases of multiple neurotransmitters-A rat microdialysis and electrophysiology study. Eur Neuropsychopharmacol 2013;23:133-45
9. Mørk A, Pehrson A, Brennum LT, et al. Pharmacological Effects of Lu AA21004: A Novel Multimodal Compound for the Treatment of Major Depressive Disorder. J Pharmacol Exp Ther 2012;340:666-75
10. Sanchez C, Asin KE, Artigas F. Vortioxetine, a novel antidepressant with multimodal activity: Review of preclinical and clinical data. Pharmacol Ther 2015;145:43-57
11. Mørk A, Montezinho LP, Miller S, et al. Vortioxetine (Lu AA21004), a novel multimodal antidepressant, enhances memory in rats. Pharmacol Biochem Behav 2013;105:41-50
12. Meyer JH. Imaging the serotonin transporter during major depressive disorder and antidepressant treatment. J Psychiatr Neurosci 2007;32:86-102
13. Areberg J, Luntang-Jensen M, Søgaard B, Nilausen DØ. Occupancy of the serotonin transporter after administration of Lu AA21004 and its relation to plasma concentration in healthy subjects. Basic Clin Pharmacol Toxicol 2012;110:401-4
14. Stenkrona P, Halldin C, Lundberg J. 5-HTT and 5-HT(1A) receptor occupancy of the novel substance vortioxetine (Lu AA21004). A PET study in control subjects. Eur Neuropsychopharmacol 2013;23:1190-8
15. Sanacora G, Treccani G, Popoli M. Towards a glutamate hypothesis of depression: An emerging frontier of neuropsychopharmacology for mood disorders. Neuropharmacology 2012;62:63-77
16. Citrome L. Vortioxetine for major depressive disorder: A systematic review of the efficacy and safety profile for this newly approved antidepressant-what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract 2014;68:60-82. Provides a thorough review of vortioxetine's clinical trials with thoughtful statistical analyses.
17. Berhan A, Barker A. Vortioxetine in the treatment of adult patients with major depressive disorder: A meta-analysis of randomized double-blind controlled trials. BMC Psychiatry 2014;14:276
18. Llorca PM, Lancon C, Brignone M, et al. Relative efficacy and tolerability of vortioxetine versus selected antidepressants by indirect comparisons of similar clinical studies. Curr Med Res Opin 2014;30:2589-606
19. Alvarez E, Perez V, Dragheim M, et al. A double-blind, randomized, placebocontrolled, active reference study of Lu AA21004 in patients with major depressive disorder. Int J Neuropsychopharmacol 2012;15:589-600
20. Katona C, Hansen T, Olsen CK. A randomized, double-blind, placebocontrolled, duloxetine-referenced, fixeddose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. Int Clin Psychopharmacol 2012;27:215-23
21. Baldwin DS, Loft H, Dragheim M. A randomised, double-blind, placebo controlled, duloxetine-referenced, fixeddose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD). Eur Neuropsychopharmacol 2012;22:482-91
22. Mahableshwarkar AR, Jacobsen PL, Chen Y. A randomized, double-blind trial of 2. 5mg and 5mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder. Curr Med Res Opin 2013;29:217-26
23. Boulenger JP, Loft H, Olsen CK. Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: A randomized, double-blind, placebocontrolled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder. Int Clin Psychopharmacol 2014;29:138-49
24. Mahableshwarkar AR, Jacobsen PL, Chen Y, et al. A randomized, doubleblind, duloxetine-referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD. Psychopharmacology (Berl) 2015;DOI 10. 1007/s00213-014-3839-0. [Epub ahead of print]
25. Henigsberg N, Mahableshwarkar AR, Jacobsen P, et al. A randomized, doubleblind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder. J Clin Psychiatry 2012;73:953-9
26. Jain R, Mahableshwarkar AR, Jacobsen PL, et al. A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5mg vortioxetine in adults with major depressive disorder. Int J Neuropsychopharmacol 2013;16:313-21
27. Boulenger JP, Loft H, Florea I. A randomized clinical study of Lu AA21004 in the prevention of relapse in patients with major depressive disorder. J Psychopharmacol 2012;26:1408-16
28. Baldwin DS, Hansen T, Florea I. Vortioxetine (Lu AA21004) in the longterm open-label treatment of major depressive disorder. Curr Med Res Opin 2012;28:1717-24
29. Alam MY, Jacobsen PL, Chen Y, et al. Safety, tolerability, and efficacy of vortioxetine (Lu AA21004) in major depressive disorder: results of an openlabel, flexible-dose, 52-week extension study. Int Clin Psychopharmacol 2014;29:36-44
30. Montgomery SA, Nielsen RZ, Poulsen LH, Häggstrom L. A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine. Hum Psychopharmacol 2014;29:470-82
31. Wang G, Gislum M, Filippov G, Montogmery S. Comparison of vortioxetine versus venlafaxine XR in adults in Asia with major depressive disorder: A randomized, double-blind study. Curr Med Res Opin 2015;doi:101185/03007995. 2015. 1014028
32. Dale E, Zhang H, Leiser SC, et al. Vortioxetine disinhibits pyramidal cell function and enhances synaptic plasticity in the rat hippocampus. J Psychopharmacol 2014;28:891-902
33. du Jardin KG, Jensen JB, Sanchez C, Pehrson AL. Vortioxetine dosedependently reverses 5-HT depletioninduced deficits in spatial working and object recognition memory: A potential role for 5-HT1A receptor agonism and 5-HT3 receptor antagonism. Eur Neuropsychopharmacol 2014;24:160-71
34. Jensen JB, du Jardin KG, Song D, et al. Vortioxetine, but not escitalopram or duloxetine, reverses memory impairment induced by central 5-HT depletion in rats: evidence for direct 5-HT receptor modulation. Eur Neuropsychopharmacol 2014;24:148-59
35. Wallace A, Pehrson AL, Sánchez C, Morilak DA. Vortioxetine restores reversal learning impaired by 5-HT depletion or chronic intermittent cold stress in rats. Int J Neuropsychopharmacol 2014;17:1695-706
36. Theunissen EL, Street D, Højer AM, et al. A randomized trial on the acute and steady-state effects of a new antidepressant, vortioxetine (Lu AA21004), on actual driving and cognition. Clin Pharmacol Ther 2013;93:493-501
37. McIntyre RS, Lophaven S, Olsen CK. A randomized, double-blind, placebocontrolled study of vortioxetine on cognitive function in depressed adults. Int J Neuropsychopharmacol 2014;17:1557-67
38. Mahableshwarkar A, Zajecka J, Jacobson W, et al. A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder. Neuropsychopharmacol 2015;doi: 10. 1038/npp. 2015. 52
39. Raskin J, Wiltse CG, Siegal A, et al. Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: An 8-week, double-blind, placebocontrolled trial. Am J Psychiatry 2007;164:900-9
40. Pearce EF, Murphy JA. Vortioxetine for the treatment of depression. Ann Pharmacother 2014;48:758-65
41. Jacobsen P, Mahableshwarkar AR, Chen Y, et al. Vortioxetine versus escitalopram in adults with well-treated major depressive disorder experiencing treatment-emergent sexual dysfunction. Eur Neuropsychopharmacol 2014;24:S464-5. Suggests that vortioxetine may potentially reverse SSRI-induced sexual dysfunction.
42. Wang Y, Nomikos GG, Karim A, et al. Effect of Vortioxetine on Cardiac Repolarization in Healthy Adult Male Subjects: Results of a Thorough QT/ QTc Study. Clin Pharm in Drug Dev 2013;2:298-309
43. Turner MS, May DB, Arthur RR, Xiong GL. Clinical impact of selective serotonin reuptake inhibitors therapy with bleeding risks. J Intern Med 2007;261:205-13
44. Nagatomo T, Rashid M, Abul Muntasir H, Komiyama T. Functions of 5-HT2A receptor and its antagonists in the cardiovascular system. Pharmacol Ther 2004;104:59-81
45. McIntyre RS, Cha DS, Soczynska JK, et al. Cognitive deficits and functional outcomes in major depressive disorder: determinants, substrates, and treatment interventions. Depress Anxiety 2013;30:515-27
46. Bortolato B, Carvalho AF, McIntyre RS. Cognitive dysfunction in major depressive disorder: A state-of-the-art clinical review. CNS Neurol Disord Drug Targets 2014;13:1804-18
47. Alvarez E, Perez V, Artigas F. Pharmacology and clinical potential of vortioxetine in the treatment of major depressive disorder. Neuropsychiatr Dis Treat 2014;10:1297-307
48. Garnock-Jones KP. Vortioxetine: A review of its use in major depressive disorder. CNS Drugs 2014;28:855-74
49. European Medicines Agency: EMA/699150/2013-Committee for Medicinal Products for Human Use (CHMP) 2013. Brintellix-Assessment report for an initial marketing authorisation application. Available from: http://www. ema. europa. eu/docs/en-GB/ document-library/EPAR--Public- assessment-report/human/002717/ WC500159447. pdf [Last accessed 15 April 2015]
50. Serretti A, Chiesa A. Treatment-emergent sexual dysfunction related to antidepressants: A meta-analysis. J Clin Psychopharmacol 2009;29:259-66
51. Taylor D, Sparshatt A, Varma S, Olofinjana O. Antidepressant efficacy of agomelatine: meta-analysis of published and unpublished studies. BMJ 2014;348:g1888